Persistence of balloon-induced arterial injury with hyperlipidemia despite gemfibrozil

Japanese Heart Journal

Volumn 37, Issue 1, 1996, Pages 119-126

  Lundgren, Craig ^a   Sobel, Burton E ^a   Fujii, Satoshi ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arterial injury; Gemfibrozil; Hyperlipidemia

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; GEMFIBROZIL; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; BALLOON DILATATION; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; FIBRINOLYSIS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID METABOLISM; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RESTENOSIS; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR SMOOTH MUSCLE;

EID: 0029930571     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/ihj.37.119     Document Type: Article

References (18)

1. Ellis SG, Cowley MJ, DiSiascio G, et al. and the Multivessel Angioplasty Prognosis Study Group. Determinants of 2-year outcome after coronary angioplasty in patients with multivessel disease on the basis of comprehensive preprocedural evaluation. Circulation 1991; 83: 1905-14.
2. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med 1986; 314: 488-500.
3. Bocan TMA, Bak Mueller S, Uhlendorf PD, et al. Dietary and mechanically induced rabbit iliac-femoral atherosclerotic lesions, a chemical and morphologic evaluation. Exp Mol Pathol 1991; 54: 201-77.
4. Allain CC, Poon LS, Chan CSG, et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-5.
5. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973; 19: 476-82.
6. Manderson JA, Mosse, PRL, Safstrom JA, Young SB, Gampbell GR. Balloon catheter injury to rabbit carotid artery. 1. Changes in smooth muscle phenotype. Arteriosclerosis 1989; 9: 289-98.
7. Sawa H, Tokuchi F, Mochizuki N, et al. Expression of the angiotensinogen gene and localization of its protein in the human heart. Circulation 1992; 86: 138-46.
8. Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-45.
9. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Program: I. Reduction in the incidence of coronary heart disease. JAMA 1984; 251: 351-64.
10. Fujii S, Sobel BE. Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor type 1. Circulation 1992; 85: 1888-93.
11. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-40.
12. Brown G, Alberts JJ, Fisher LD, et al. Regression of coronary artery disease as the result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1337-9.
13. Multiple Risk Factor Intervention Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. N Engl J Med 1982; 248: 1465-77.
14. Strandberg TE, Salomaa VV, Naukkarinen VA, et al. Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men. JAMA 1991; 266: 1225-9.
15. Carlson LA, Rosenhamer G. Reduction in mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405-18.
16. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIPT) Circulation 1994; 89: 975-990.
17. Watts GF, Lewis B, Brent JNH, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas Arteriosclerosis Regression Study (STARS). Lancet 1992; 339: 563-9.
18. Bocan TM, Mueller SB, Uhlendorf PD, et al. Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation. Arterioscler Thromb 1991; 11: 1830-43.